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Abstract:
OBJECTIVES: The primary aim of this study was to investigate whether ovarian cancer patients
in Kentucky are more likely to have multiple primary and synchronized primary cancers
compared to Non-Kentucky SEER registry cancer patients. A secondary aim of the study was to
determine if there are other factors that may be associated with an increased risk of having
multiple primary and synchronized cancer as well as determining if having multiple primary and
synchronous cancer diagnoses changes survival rates in ovarian cancer patients. Additionally,
another objective was to identify the most frequently observed subsequent and synchronous
cancers sites that are diagnosed in ovarian cancer patients within Kentucky.
METHODS: The data for this retrospective, population-based cohort study of 72,491 primary
ovarian cancer patients were obtained from the Kentucky Cancer Registry. To be included in the
study population, the patients from Kentucky and Non-Kentucky areas within the SEER registry
had to have been diagnosed between January 1, 2000 and December 31, 2014. Subjects were
classified as a multiple primary cancer case based on whether they were diagnosed with a second
primary cancer in addition to their first primary of ovarian cancer within the years 2000-2014.
Subjects were classified as a synchronous cancer case if they were diagnosed with their
secondary cancer diagnosis within 6 months or less or their first diagnosis. Logistic and Cox
regression were utilized to identify factors associated with multiple primary cancer and
synchronized cancer.
RESULTS: After much investigation, the focus of this analysis turned to early stage disease and
the comparison to all stage for multiple primary and synchronous ovarian cancers. This is due to
the fact that in the analysis, an interaction was found between early stage ovarian cancer and the
location variable with Kentucky having 1.25 greater odds of being diagnosed with early stage
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ovarian cancer (adjusted OR=1.25 [95% CI (1.04, 1.5)], p=0.0364).
There were statistically significant differences in the distribution of early stage and late
stage cancer cases in patients who had multiple primaries but not for synchronous cancers
between Kentucky and SEER (early stage multiple primary p=0.0071, early stage synchronous
p=0.1008). There was also a significant association between multiple primary cancer status
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between Kentucky and SEER with Kentucky patients having a 1.23 times the odds of developing
multiple primaries compared to SEER patients; adjusted OR=1.23, [95% CI (1.02, 1.47)].
The Cox proportional hazard model for multiple primary cancer adjusted for early stage
revealed that there were no statistically significant differences between Kentucky and SEER in
regards hazard of being diagnosed with a multiple primary cancer (adjusted OR=1.04 [95% CI
(0.91, 1.19)]).
There were no survival differences seen between Kentucky and SEER for multiple primary cases
(log-rank test=0.7093). There were also no survival differences seen between Kentucky and
SEER for synchronous cancer cases (log-rank test: 0.8419). Survival curves were also
constructed for early stage of disease for both multiple primary and synchronous cancer cases
and no differences were seen (log-rank test: 0.5805 and log-rank test: 0.9833). Survival
differences were seen when comparing Kentucky and SEER for both multiple primary and
synchronous cancer cases with Kentucky having much lower survival in both cases (log-rank
test: 0.0329 and log-rank test: 0.0353).
CONCLUSIONS: Based on the results from the Cox proportional hazard model, primary
ovarian cancer patients living in Kentucky are not at a greater risk of having multiple primary
cancers than those residing in Non-Kentucky SEER areas, regardless of stage of disease. When
observing the results from the logistic model for early stage of disease, the results indicate that
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Kentucky is at a greater risk for developing early stage multiple primary cancers in comparison
to Non-Kentucky SEER. This difference could be due to the fact that a large number of
observations had to be deleted due to the fact that date of diagnosis for the secondary cancer for
these patients could not be obtained because the information was not in the database. High risk
groups identified in this study are women who were diagnosed in earlier years, were older, white,
single, lived in an urban area, had grade I cancer, and those who had sex chord-stromal tumors.
Further analyses are needed to determine the definitive implications of the higher proportions of
early stage cancer within Kentucky.
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Introduction:
Ovarian cancer is the leading cause of deaths from gynecologic cancers. An estimated
14,080 ovarian cancer deaths will occur in 2017. Ovarian cancer accounts for about 5% of the
cancer deaths among women. Even though this is a small percentage, ovarian cancer is an
extremely aggressive and very fatal cancer. The 5-year relative survival rate for ovarian cancer
is relatively low (46%) and this is due to the fact that most patients (60%) are diagnosed with
distant-stage disease, for which survival is 29%. For the 15% of patients diagnosed with
localized disease, 5-year survival is 92%. Survival varies significantly by age, with women
younger than 45 much more likely to survive 5 years than women 75 and older (77% versus
20%).1 Although survival for women with ovarian cancer has improved over the past few
years, this has allowed for the opportunity for increases in the occurrence of second malignant
neoplasms.18
It is estimated that on January 1, 2005 within the US that there were 880,300 cancer
survivors who had been diagnosed with more than one cancer.28 Second primary cancers
diagnoses are seen in about 15% of cancer survivors overall, which can result in increased
morbidity and mortality.20 A study published in the 2009 edition of the European Journal of
Cancer Prevention showed a significant excess risk of second neoplasms in women who were
diagnosed with invasive or borderline ovarian cancers. Most of this excess was found to be
attributable to synchronously diagnosed neoplasms (cancers diagnosed in the same time period
as the index ovarian cancer).16 Another study published in 2007 in the Journal of Modern
Pathology found that ovarian cancer patients had an increased risk for developing synchronous
cancers.19
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For most epidemiological studies, cases are classified as multiple primary malignancies if
they arise in different sites or they have a different histology or morphology type. This definition
helps avoid any misclassification of tumors that are not multiple primaries as such.35 For this
study, the SEER database defines multiple primaries as follows: 1) two or more separate
neoplasms in different topographic sites 3) certain conditions that are characterized by multiple
tumors 3) lymphomas, which often involve multiple lymph nodes or organs at diagnosis 4) two
or more neoplasms of different morphology arising in the same site 5) a single neoplasm
involving multiple sites whose precise origin cannot be determined.25In most cases, researchers
define synchronous cancers as cancers that are diagnosed less than 6 months from first cancer
diagnosis. One study in particular defined synchronous cancer cases as “2 diagnoses at once or
less than 6 months of the first cancer diagnosis”.13
According to an article published in the 2003 edition of the Journal of American Cancer
Society, multiple cancer diagnoses may be caused by inherited or acquired cellular lesions or
deficiencies, that can be caused by environmental exposures to carcinogens. The article also
states that these diagnoses can be linked or completely independent of their first primary
malignancy.7 Additionally, ovarian tumors as well as breast, endometrial, and colon cancers
have been shown to be linked reproductive hormones. Both genetic and other reproductive
factors have also been shown to contribute to increased risk of second primary malignancies
especially breast, colorectal, and melanoma.16 None of these factors were assessed in this
study.
Results from a study published in the 2015 issue of the Journal of Medicine (Baltimore)
demonstrated that that the risk of second primary malignancy is significantly higher in patients
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diagnosed with ovarian cancer. Age, chemotherapy, and radiotherapy (treatment) were all
independent risk factors for second primary malignancies in this population.11
Although research has been conducted regarding treatment and risk factors for ovarian
cancer, very little has been done to assess the status of ovarian cancer within Kentucky
compared to other areas in regards to risk of second primary diagnosis or time to second cancer
diagnosis. While rates are particularly low within Kentucky compared to many other
cancers,6,29 ovarian cancer still remains at the top of the list for being the cause of more deaths
in women than any other gynecologic cancer. Additionally, in 2016 Kentucky was ranked the
highest within the Unites States for cancer burden.3 Comparing Kentucky to all Non-Kentucky
SEER populations is also important due to the major differences in the areas. Kentucky is a
largely rural population in comparison to the more urban populations that exist in the other 16
SEER regions in this study. Kentucky has also been identified as having major health disparities
and has been designated as a special population by the National Cancer Institute.26 Therefore, it
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is especially important to determine whether case distribution and survival differences do exist
from cancers like ovarian cancer in Kentucky compared to the rest of the SEER registered
population.
Also, due to generally low survival rates in ovarian cancer patients, second primary
diagnoses are not usually studied. The fact that other studies have found an increased risk for
second primary malignancies for ovarian cancer patients and that historically Kentucky has
been at an increased risk incident cancer diagnoses, it is important to determine if there are
differences in the distribution of multiple primary cancer cases, risk factors, and survival
between the Kentucky population and all other SEER registry population overall. Since
ovarian cancer patients have also been shown to be at an increased risk for developing
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synchronous cancer, we decided to expand our investigation to assess if there were these
differences for synchronous cancers as well.
Methods:
Study Population and Design
This was a retrospective, population-based cohort study of 72,491 first primary ovarian
cancer patients, 3671 patients from Kentucky and 68,820 patients from overall SEER (all areas
excluding Kentucky). These patients were aged 20 years and older, that all had previously been
diagnosed with a primary of ovarian cancer between January 1, 2000 and December 31, 2014.
Ovarian cancer patients in Kentucky were chosen as the target population, due to the fact that
ovarian cancer is the highest in mortality rates for gynecologic cancers. Additionally, Kentucky’s
history as far as cancer burden and mortality in general makes the area an ideal population to
study. The study population was drawn from the Kentucky Cancer Registry, which is both an
NCI Surveillance, Epidemiology, and End Results (SEER) cancer registry and a CDC National
Program of Cancer Registries (NPCR) participant.32
Subjects were classified as a multiple primary cancer case based on a sequence number in
the database and whether they received their secondary cancer diagnosis in between 2000-2014
after having a first primary diagnosis of ovarian cancer. To be classified as a synchronous cancer
case, subject had to have been diagnosed with a second cancer in 6 months or less from their first
diagnosis of ovarian cancer. Additionally, subjects were classified as a non-synchronous case if
they had only one primary diagnosis or if they had a second cancer diagnosis in greater than 6
months from their first diagnosis of ovarian cancer. A review of previous literature was
conducted and the grouping of histology codes was based on the results found from previous
studies and guidelines.9, 15, 37
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The subjects from both Kentucky and SEER registered patients (non-Kentucky areas)
were followed to determine if they had differences in survival based on their multiple primary
and synchronous cancer status as well as how important risk factor variables contributed to these
differences. The primary hypothesis of this study was that Kentucky patients would have greater
proportions of multiple primary and synchronous cancers as well as a decreased overall survival
when compared to other SEER registered patients. The study also examined other factors
associated with the development of multiple primary and synchronous cancers in ovarian cancer
patients.
This study was approved by the Institutional Review Board of the University of
Kentucky (# 43510) and received Exemption Certification for Protocol No. 43510.
Data Analysis
SEER*Stat version 8.3.4 was used to identify eligible patients to be included in the
study.31 Statistical analyses were carried out using SAS version 9.4. Descriptive analyses for
univariate distributions were reported as sample size, percent, means, medians, standard
deviations, quartiles, minimum and maximum values were examined for continuous variables.
For categorical variables, frequencies and percentages were calculated. Results were examined
by main exposure (concurrence cancer diagnosis status), in both Kentucky and all other SEER
registry areas and a comparison was made between the two groups. Using non-Kentucky SEER
status as the reference group, bivariate distributions between risk factors and exposure were
assessed using chi-square p-value and Fisher’s Exact for those cell counts that were less than 5 in
magnitude. Logistic regression analyses were conducted to examine whether Kentucky status is
associated with multiple primary and synchronized cancer status while controlling for other
factors.
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A Cox proportional hazard model was utilized in order to determine if there was an
association between potential risk factors as well as the region in which the patients lived and the
likelihood of developing multiple primary cancers. Kaplan-Meier method was used to produce
survival curves. The log-rank P-value was utilized to assess differences between the estimated
survival curves. All tests were evaluated using a two-sided significance level of 5%.

Results:
Descriptive Statistics/Univariate Findings
There were 3,671 women from Kentucky and for women in non-Kentucky SEER there
were 68,820 in the sample size. Additionally, the results show that from 5,377 patients diagnosed
as a multiple primary ovarian case, that 2,489 cases manifested as a synchronous malignancy
(46.3%) which is consistent with the current literature.14 Results from Table 1 show that of
women in Kentucky and SEER, the majority of the women were in the aged 50-64 (32.8% and
34.6%). As year of diagnosis increased, the number of cases of ovarian cancer for Kentucky and
for SEER the cases decreased and then increased again up to 2014. The majority of the women
were white with 95.2% in Kentucky and 82.7% in SEER. For Kentucky, 30.8% of women lived
in an Appalachian region. Appalachian status was not calculated for women in non-Kentucky
SEER due to the fact that only 2 out of 16 regions included in the Non-Kentucky SEER group
had Appalachian regions. Within Kentucky, the distribution of patients in rural and urban areas
was divided almost evenly with 53.6% of the women living in urban areas. In SEER, 90.2% of
the women were living in urban areas. In both Kentucky and SEER, most of the women were
married (44.6% and 48.2%). Of all of the cases in Kentucky and SEER, only 7.8% and 7.4%
were multiple primaries and synchronous cases consisted of 3.8% and 3.4% of the sample size.
Most of the women had late stage disease with 54.9% in Kentucky and 57.1% in SEER. In both
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Kentucky and SEER, of the women with known grade of disease, most of the women had grade
III disease (Kentucky: 27.4% and SEER: 30.2%). Finally, the most frequently observed histology
type in both areas was epithelial tumors (Kentucky: 61.8% and SEER: 64.2%).

Multiple Primary Cancer Diagnoses

Table 2 demonstrates the distribution of multiple primary cancers within each region by
stage. Within Kentucky, 15.1% of the 285 multiple primary cancer cases were early stage
compared to the 12.3% early stage multiple primary cases in Non-Kentucky SEER. Additionally,
within early stage of disease, there were found to be statistically significantly differences
between Kentucky and SEER for distributions of multiple primary cancer cases (p= 0.0071).
There were no statistically significant differences for multiple primary cases for late stage
disease.

Table 3 shows that of the women from Kentucky, 7.8% had multiple primary cancers
compares to 7.4% from the SEER areas. Most of these women were aged 50-64 (40.4% in KY
and 41% in SEER), were white (95.4% in KY and 85.1% in SEER), lived in an urban area
(55.4% in KY and 91% in SEER), were married (44.9% in KY and 52.2% in SEER), had early
stage of disease (56.1% in KY and 45.1% in SEER), had grade III disease (32.6% in KY and
30.7% in SEER), and had epithelial tumors (71.9% in KY and 74.2% in SEER). Additionally, for
those women with multiple primary cancers in Kentucky, 67.4% were living in Non-Appalachian
areas.
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Synchronous Cancer Diagnoses

Table 2 also shows the distribution of synchronous cancers within each region by stage of
disease. Within Kentucky, 7.4% of the 285 multiple primary cases were early stage synchronous
cases compared to the 6.1% early stage synchronous cases in Non-Kentucky SEER. Also, within
early stage of disease, there were no statistically significantly differences between Kentucky and
SEER for distributions of synchronous cancer cases (p= 0.0950). Additionally, there were no
statistically significant differences for synchronous cases for late stage disease.

Table 4 depicts the results for the distribution of synchronous cancer cases by location.
From the total sample size and for patients with synchronous cancer diagnoses, 3.9% were from
Kentucky and 3.5% were from SEER areas. Similar to the women with multiple primaries, of the
synchronous cases most women were aged 50-64 (34.5% in KY and 39.2% in SEER), were
white (97.1% in KY and 84% in SEER), lived in an urban area (54.7% in KY and 91.8% in
SEER), were married (46.8% in KY and 49.7% in SEER), had early stage of disease (54.7% in
KY and 47.5% in SEER), had grade III disease (30.9% in KY and 24.9% in SEER), and had
epithelial tumors (73.4% in KY and 71.8% in SEER). Additionally, for those women with
synchronous cancer diagnoses in Kentucky, 66.2% were living in Non-Appalachian areas.
Most Frequently Observed Cancer Sites for Multiple Primary and Synchronous Ovarian
Cancer Cases

The most frequently observed type of multiple primary diagnosis was uterine cancer
(31.2% in KY and 56.3% in SEER), followed by breast (13.7% in KY and 7.5% in SEER) lung
and bronchus (4.9% in KY and 2.4% in SEER), and ovary (second primary malignancy but same
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site as first primary) (4.6% in KY and 1.4% in SEER). For synchronous cancer, the most
frequently observed type of secondary cancer was uterine (61.2% in KY and 56.3% in SEER),
ovarian (7.2% in KY and 5.0% in SEER), and breast cancer (6.5% in KY and 7.5% in SEER).
There were no significant differences in the distribution between Kentucky and SEER for
multiple primary cancers (p=0.4992) but there were differences found among patients with
synchronous cancers (p=0.0443).

Findings from Logistic Regression Models and Patient Survival
After much investigation, the focus of analysis turned to early stage disease and the
comparison to all stage ovarian cancer. This is due to the fact that in the analysis, an interaction
was found between early stage ovarian cancer and the location variable with Kentucky having
1.25 greater odds of being diagnosed with early stage ovarian cancer (adjusted OR=1.25 [95% CI
(1.04, 1.5)], p=0.0364). This lead to the logistic modeling of both multiple primary and
synchronous cancer cases adjusting for early stage of disease. Early stage disease was classified
as stage I and stage II ovarian cancer and late stage was classified as stage III and stage IV.
Unknown stage was not included within the logistic or Cox proportional hazard models.
There were statistically significant differences in the distribution of early stage and late
stage cancer cases between Kentucky and SEER but only in patients with multiple primary
cancers (Table 2- early stage multiple primary p=0.0071) Early and late stage synchronous
cancers were not statistically different between Kentucky and SEER (Table 2- early stage
synchronous p=0.0950.
Results from the logistic model for early and late stage in Table 6 indicate that there were
no significant differences in the odds of developing multiple primary cancers between Kentucky
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and SEER (adjusted OR= 1.06 [95% CI (0.93, 1.22)] p=0.4008).
Table 6 also shows the results from the logistic model with multiple primary cancers for early
stage only. When adjusting for early stage, there were significant differences in the odds of
developing multiple primary cancers between Kentucky and SEER, with Kentucky patients
having a 1.23 greater odds of developing early stage multiple primaries compared to SEER
patients; adjusted OR=1.23, [95% CI (1.02, 1.47)]. Women with early stage disease and aged 6574 had a 1.16 increase in odds adjusted OR=1.16, [95% CI (1.08, 1.33)]. and those aged 75+ had
a 14% decrease in odds adjusted OR=0.86, [95% CI (0.72, 1.03)] of having a multiple primary
diagnosis when compared to women aged 20-49. These two age groups were the only ones with
statistically significant differences. For early stage disease, the year these women were diagnosed
modeled as a continuous variable in the logistic model also proved to be statistically significant
(adjusted OR=0.93 [95% CI (0.94, 0.96)], p = <0.0001). There were no significant results
regarding race in the model except for the unknown category. When compared to patients with
grade I disease, patients with grade II, grade III and grade IV proved to be statistically significant
in the model with grade II patients having an 6% decrease in odds (adjusted OR=0.94, [95% CI
(0.83, 1.06)]), grade III patients having a 31% decrease in odds (adjusted OR= 0.69 [95% CI
(0.63, 0.77)]), and grade IV patients having a 37% decrease in odds (adjusted OR=0.63 [95% CI
(0.56, 0.72)]) of being diagnosed with multiple primary cancers. Additionally, when compared to
patients with epithelial tumors, patients with sex-chord-stromal and germ cell tumors had results
that were statistically significant. Patients with sex-chord-stromal tumors had 1.06 times
increased odds (adjusted OR=1.06 [95% CI (0.93, 1.22)]) and patients with germ cell tumors had
a 72% decrease in odds of being diagnosed as a multiple primary cancer (adjusted OR=0.28
[95% CI (0.20 0.40)]).

17
Table 7 shows the logistic models for early and late stage synchronous cancer cases did
not show statistically significant results regarding the location of the patient (adjusted OR 1.14
[95% CI (0.94, 1.38)] p=0.1949). Table 7 also showed results for the adjusted model for
synchronous cancer which was adjusted for early stage of disease. There were no significant
associations between synchronous cancer status between Kentucky and SEER in the adjusted
model; adjusted OR=1.133, [95% CI= (0.943, 1.361)] p=0.1008.
There was no Cox proportional hazard analysis conducted on synchronous cancers due to
the fact that it was dichotomous at 6 months and this was a very short amount of time for followup.
A Cox proportional hazard model was conducted to allow for the control of variables
that could potentially be confounding as well as allowing the censoring cases of death due which
otherwise would not have been possible with a logistic regression model only. Again, the focus
of this analysis was early stage verses all stage cancer cases due to the previously mentioned
interaction that was found. The Cox proportional hazard model for multiple primary cancer for
early and late stage in Table 8 showed that there were no statistically significant differences
between Kentucky and SEER in the hazard of being diagnosed with a multiple primary cancer
(adjust OR=1.06 [95% CI (0.92, 1.22)]).
There were also no differences between Kentucky and SEER seen in Table 8 for the Cox
proportional hazard model for multiple primary cancer adjusted for early stage in regards to the
hazard of being diagnosed with a multiple primary cancer (adjust OR=1.04 [95% CI (0.91,
1.19)]). There were statistically significant results in the model adjusting for early stage with
regards to age groups 50-64 and 65-74. Women aged 50-64 had a 1.14 increase in hazards of
death compared to women who were aged 20-49 and women who were aged 65-74 had a 1.19
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increase in hazards of death when compared to women aged 20-49. Year of diagnosis was also
statistically significant in this model ((adjusted OR=1.04 [95% CI (0.91, 1.19)] p=<0.0001). For
early stage patients compared to white women, black women had a 12% decrease (adjusted
HR=0.88 [95% CI (0.78, 0.99)]) and other women (American Indian/ AK Native, Asian/Pacific
Islander) had a 14% decrease in hazards of being diagnosed as a multiple primary case (adjusted
HR=0.86 [95% CI (0.77, 0.96)]). There were no statistically significant results for urban status
within the model.
When compared to being single, married women with early stage cancer had a 16%
decreased hazard (adjusted HR=0.84 [95% CI (0.77, 0.91)]), separated or divorced women had a
14% decreased hazard (adjusted HR=0.86 [95% CI (0.77, 0.97)]), and widowed women had a
15% decreased hazard of being diagnosed with a multiple primary cancer (adjusted HR=0.85
[95% CI (0.76, 0.96)]). Compared to women with grade I disease, women with early stage
disease and grade III had a 31% decrease (adjusted HR=0.69 [95% CI (0.63, 0.77)]) and women
with grade IV had a 40% decrease in hazards of having a multiple primary cancer diagnosis
(adjusted HR=0.60 [95% CI (0.53, 0.69)]). When compared to women with epithelial tumors,
women with early stage disease and sex chord-stromal tumors had a 1.13 increase (adjusted
HR=1.13 [95% CI (1.02, 1.26)]) and women with germ cell tumors had a 64% decreased hazard
of developing multiple primary cancer (adjusted HR=0.36 [95% CI (0.27, 0.48)]).
There were no survival differences seen between Kentucky and SEER for multiple
primary cases (log-rank test=0.7093). There were also no survival differences seen between
Kentucky and SEER for synchronous cancer cases (log-rank test: 0.8419). Survival curves were
also constructed for early stage of disease for both multiple primary and synchronous cancer
cases and no differences were seen (log-rank test: 0.5805 and log-rank test: 0.9833). Survival
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differences were seen when comparing Kentucky and SEER for both multiple primary and
synchronous cancer cases with Kentucky having much lower survival in both cases (log-rank
test: 0.0329 and log-rank test: 0.0353).
Discussion:
Research has shown that health disparities do exist within Kentucky and given the special
populations designation by the National Cancer Institute for this area27 and that it is especially
important to assess whether case distribution and survival differences do exist from cancers like
ovarian cancer in Kentucky compared to the rest of the SEER registered areas.
To our knowledge, this is the first study that has examined the risk factors and survival
differences for multiple and synchronous ovarian cancer cases within this population. Where
overlap in findings from other studies existed, our findings were similar to the findings of
previous studies that used SEER guidelines to define multiple primary and synchronous cancers.
Location variable
This study showed that when adjusting for early stage of disease, there were significant
differences between Kentucky and SEER with regards to risk of developing early stage multiple
primary malignancies but only within the logistic regression model. In the Cox regression model
for multiple primary malignancies, the results for early stage of disease was not statistically
significant. This is most likely due to the fact that there was a number of observations that had to
be deleted because no date of second diagnosis or other follow-up information was available on
these patients. Additionally, a lot of these patients may have died or just not had enough time to
develop other primary cancers. Given the fact that the odds ratio in the logistic model and the
hazard rate in the Cox regression for early stage cancer within Kentucky are both greater than
one, the results might have otherwise been significant. Within Kentucky, there were a greater
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proportion of early stage multiple primary and synchronous cancers when compared to NonKentucky SEER. This may be due to the Ovarian Cancer Screening Program Trial that has been
ongoing since 1987 at the University of Kentucky. Their use trans-vaginal sonography along
with serum CA-125 testing has proved to be incredibly effective for earlier detection of ovarian
cancer.33,35 A study published in 2011 in the Journal of Obstetrics & Gynecology evaluating long
term survival of the women within the trial found results that indicate that the annual screening
for at risk women caused a decrease in the stage at detection and site-specific ovarian cancer
mortality when compare to women from the same area who did not have annual screenings.33
These results give indications that patients in Kentucky are getting diagnosed at an earlier stage
and therefore have longer survival and more opportunity to develop secondary cancers.

Age
Results from this study revealed when adjusting for early stage of disease that there was
an increased risk for developing multiple and synchronous after a first primary of ovarian cancer
if patients were aged 50-64 and 65-74. There was a decrease in risk in the 75+ group and this
could be due to the lower survival in this age group and that they did not have time to develop a
secondary cancer. For patients diagnosed with synchronous cancer along with the first primary
ovarian cancer, there was also a decrease in odds in for women aged 75+. In the same previously
mentioned article published in the North American Association of Central Cancer Registries
Journal, patients with multiple primary ovarian cancers were found to be older in comparison to
those who had a single primary.3 Interestingly, two other studies Suris-Swartz et al. and Sheu et
al. found opposite results for patients with multiple primary ovarian cancers. These studies (who
reported only on synchronous tumors) were found to be younger. 26, 30
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No other statistically significant results were found within age for women who had
synchronous cancers.
Year of diagnosis
The results showed statistically significant results for both multiple primary and
synchronous cases. The overall trend for multiple primary cancers was a decrease in cases as the
years increased from 2000-2014. This indicates that patients diagnosed in earlier years were
more likely to develop other cancers simply because they survived longer and had greater
opportunity. For synchronous cancers cases, the number of cases increased as the years
increased. This can most likely be attributed to increased screening and diagnosis methods.
While there is still not a great screening method for ovarian cancer, over the past few years there
has been an increase in surveillance and knowledge about risk factors for the disease. Significant
progress has been made especially in regards to the diagnosis and treatment of women with
ovarian cancer in the last few years and the effects are just now being observed.21 This can
particularly be seen in this study in the Cox regression model for multiple primary cancers; the
odds ratio for year of diagnosis increased which also indicates an increase in synchronous
cancers in recent years. This could mean that most of these women who are being screened in
recent years, are having their cancers diagnosed due to better screening methods in the past few
years.
Race
Interestingly, the results from the logistic models for early stage synchronous and
multiple primary malignancies did not indicate statistical significance but the results from the
Cox regression model for multiple primary cancers did. Overall, the results were consistent with
previously mentioned literature that have found that the majority of ovarian cancer patients are
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white females.11 Also, the majority of women in Kentucky were white while within SEER there
was more of mixture of races in the population. This is because Kentucky is not as diverse of a
population in regards to race when compared to the rest of the SEER registry.
Marital status
Marital status was not significant within the logistic models for multiple primary and
synchronous cancers but it was significant in the cox regression model for multiple primary
cancers for both early stage only and early and late stage. The overall trend demonstrated that
when compared to single women, married, separated/divorced, and widowed women had a
decrease in hazards of being diagnosed as an early stage multiple primary.
Grade
Grade of disease was consistently significant in both the logistic models for multiple
primary and synchronous cancers as well as in the Cox regression model for multiple primary
cancer. Generally, earlier grade of disease is associated with slower growing cancers and
generally better survival.2 These results are consistent with previous findings that these patients
are may be surviving longer and therefore have greater opportunity to develop other cancers.
Histology

Patients with sex chord-stromal tumors consistently had an increase in odds of being
diagnosed with multiple and synchronous cancers. Also within the Cox proportional hazard
model for multiple primary cases, patients with this histology type were more likely to be
diagnosed at an earlier stage of disease. It is interesting because this histology of ovarian cancer
is less common than other histology types but also tends to present as low-grade and less
aggressive.10, 13 One study published in 2009 found that improved survival in sex chord-stromal
ovarian tumors and attributed the results to a stage-shift toward more favorable stages at
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diagnosis and advances in treatment such as improved surgery with no residual tumors.13 These
result align with the conclusions that this increase in survival gives these patients more time to
develop secondary cancers and makes them at higher for multiple primary cancer diagnoses.
Strengths
The current descriptive study provided an opportunity to study multiple primary and
synchronous ovarian cancers in a large and diverse population. Using a standard method,
population‐based data were collected from the SEER registry within the United States
population during the period 2000-2014. The large number of cases (72,491) allowed us to
examine multiple primary and synchronous ovarian cancer cases and assess important risk
factors and to compare these descriptors among locations to see if there were any differences.
Limitations
One of the important limitations in this study has to do with the data source. The use of
SEER registry data is limiting at times due to the fact that all cases and information may not be
captured. In the case of this study in particular, all synchronous or multiple primary cancer cases
may not be included in the data due to patients moving away to other areas or not receiving
information from hospitals on the patient’s current status (treatment, current disease status, etc.)
In this analysis, the biggest issue with the data was in using a Cox proportional hazard analysis in
order to model the multiple primary cancer cases. Due to the lack of information on vital status
and other important factors, a large portion of the patients had to be deleted. This occurred
because many patients who did have multiple primaries did not have the date of diagnosis of
their second cancer diagnosis or other follow-up information was not able to be obtained.
Ultimately, even though the odds ratio for the location variable showed that Kentucky was at an
increased risk for developing multiple primary malignancies, the results from the Cox
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proportional hazard model were not significant.
Another limitation is the fact that not all states are SEER registered which means that the
data did not include all areas within the United States. For this study, only 17 regions were
included in the Non-Kentucky SEER group and then Kentucky was included separately in the
analysis. Due to the fact that not all states are SEER registered, this makes the analysis limited in
the implications when applying it to other areas or other populations as a whole.

When studying multiple primary and synchronous cancers cases, there must be a high
level of accuracy in tumor registration. Even studies that used data sets that were well known to
be of very high quality were at times found to contain errors that affected interpretation
substantially.11 The classification of multiple primary tumors is incredibly difficult. In addition to
this, there is lack of agreement on a standard definition for multiple primary cancers and this
causes a great amount of confusion among researchers.11 In order to avoid this, other studies
have eliminated potential sources of error by limiting the analysis to histologically confirmed
tumors or tumors of a specific cell type (e.g., adenocarcinomas, endometrioid carcinoma), or by
defining additional exclusion criteria (e.g., excluding synchronous tumors with similar histology
types) to avoid the possibility of misclassified or misdiagnosed tumors.4,5 Even with strict
guidelines to follow, there is still the chance that cancer cases that there were classified as a
multiple primary case were done so falsely. This misclassification can potentially lead to
misinterpretation of results.
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Implications

When adjusting for early stage of disease, there were significant differences between
Kentucky and SEER with regards to risk of developing early stage multiple primary
malignancies but only within the logistic regression model. There were a greater proportion of
early stage multiple primary cancers and synchronous within Kentucky when compared to NonKentucky SEER. As previously mentioned be due to the Ovarian Cancer Screening Program
Trial that has been ongoing since 1987 at the University of Kentucky. The screening program’s
use trans-vaginal sonography along with serum CA-125 testing has proved to be incredibly
effective for earlier detection of ovarian cancer 33,35. Our study demonstrates the importance of
early detection in ovarian cancer in that more than two-thirds of asymptomatic women with
ovarian cancer detected by screening in the 2011 trial at the University of Kentucky presented
with localized disease at the time of cancer detection, and the 5-year survival rate for these
patients was nearly 90%. Without early detection, most of these women will likely go on to
present with later stage of disease which ultimately increases cost of treatment and decreases the
average cure rate.36 Interestingly, this screening method has not produces any survival
differences between early stage multiple primary or synchronous ovarian cancer cases within
Kentucky. The cause of this is most likely the fact that annual trans-vaginal sonography is not
currently recommended within the guidelines for ovarian cancer prevention. The reasoning for
this is that currently there is no evidence that any screening test, CA-125, ultrasound, or pelvic
examination, has reduced overall mortality from ovarian cancer. Additionally, despite the
existing evidence that these screening methods can detect ovarian cancer in earlier stages is not
enough evidence to demonstrate that these earlier diagnoses will reduce mortality. Furthermore,
the use of trans-vaginal sonography has some drawbacks including the invasive nature of the
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screening method and the higher rates of false diagnoses of ovarian cancers especially in women
who are only at moderate risk for the disease.23

It is also important to note that over the past few years, multiple primary cancer cases have
been decreasing. The overall trend in this study for multiple primary cancers shows a decrease in
cases as the years increase from 2000-2014. These patients are diagnosed in earlier years which
means that they were more likely to develop other cancers simply because they survived longer
and had more opportunity to do so. For synchronous cancers cases, the number of cases
decreased as the years went on from 2000-2014. This could be due to better screening and
diagnosis methods. The Cox regression model for multiple primary cancers shows that the odds
ratio for year of diagnosis increased which also indicates an increase in synchronous cancers in
the more recent years. This indicates that most of these women who are being screened recently,
are most likely having their cancers diagnosed due to better screening methods and increase in
overall surveillance over the past few years. These advances in screening methods do have
clinical implications for future health care needs. As the population increases and survival
increases for these patients, their medical care needs will morph over time. For future analyses, is
important to examine long-term treatment effects on these patients and to be aware of the issues
that impact multiple primary and synchronous cancer patients. The population of patients who
are being treated for cancer is also aging, and projections for U.S. population suggest that they
will continue to age through years to come. As a consequence, the patient population might have
increased comorbidities that will affect both treatment decisions and healthcare options during
survivorship.7
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Additionally, the results from the survival analysis for late stage cancer indicated that
there is also still a gap for the care of late stage cancers within Kentucky. Compared to NonKentucky SEER, late stage cancer multiple primary and synchronous ovarian cancer patients had
much worse survival. Like many other cancers in Kentucky, this could be due to the lower socioeconomic areas in the state and a lack of access to care such as poor health insurance coverage.
In one study conducted in 2003 on overall cancer survival in Kentucky, one major influence on
survival was health coverage.18 Another study found that for most of the cancers that were
studied, the patients from more deprived economic areas had poorer survival than those from
more advantaged areas.17,22

The focus of this study was not on late stage but early stage differences. To be able to determine
what is likely associated with these differences in late stage survival, further analyses may be
needed.

Conclusion:
Even though adjusted logistic models revealed some differences between the Kentucky
and Non-Kentucky SEER populations of ovarian cancer patients, the adjusted multivariable Cox
proportional hazard analysis indicated that there were no differences between Kentucky and
SEER patients regarding the development of multiple primary cancers. This study did provide
insight as to potential risk factors for development of multiple and synchronous cancers in
ovarian cancer patients. High risk groups identified in this study are women who were diagnosed
in earlier years, were older, white, single, lived in an urban area, had grade I cancer, and those
who had sex chord-stromal tumors. Due to the results from the Cox Regression model, further
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investigation is needed to determine definitively the implications of more early stage cancer
within Kentucky.
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Tables and Figures
Table 1. Descriptive statistics for all cases in Kentucky and SEER (N=72,491)
Kentucky

Non-Kentucky SEER
P-value

Variable

Age at diagnosis (years)
20-49
50-64
65-74
75+
Year of diagnosis
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012

(3671, 5.06%)

(68,820, 94.93%)

718 (19.6%)
1204 (32.8%)
789 (21.5%)
960 (26.2%)

14008 (20.4%)
23801 (34.6%)
14228 (20.7%)
16783 (24.4%)

0.0197

301 (8,2%)
248 (6.8%)
261 (7.1%)
234 (6.4%)
265 (7.2%)
248 (6.8%)
265 (7.2%)
240 (6.5%)
245 (6.7%)
234 (6.4%)
225 (6.1%)
235 (6.4%)
239 (6.5%)

4547 (6.6%)
4687 (6.8%)
4619 (6.7%)
4557 (6.6%)
4452 (6.5%)
4567 (6.6%)
4567 (6.6%)
4585 (6.7%)
4758 (6.9%)
4638 (6.7%)
4618 (6.7%)
4560 (6.6%)
4593 (6.7%)

0.0027
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2013
2014

235 (6.4%)
196 (5.3%)

4558 (6.6%)
4630 (6.7%)

White

3496 (95.2%)

56888 (82.7%)

Black

153 (4.2%)

5842 (8.5%)

Other (American Indian/AK
Native, Asian/Pacific Islander)

15 (0.4%)

5786 (8.4%)

Unknown

7 (0.2%)

304 (0.4%)

Appalachian

1129 (30.8%)

-

Non-Appalachian

2542 (69.3%)

-

Urban

1967 (53.6%)

62077 (90.2%)

Rural

1704 (46.4%)

6670 (9.7%)

Unknown

0 (0.0)

73 (0.11)

Race

<0.0001

*Appalachian Status (Kentucky)
-

Urban/Rural
<0.0001

Marital Status at Diagnosis
Single

465 (12.7%)

12315 (17.9%)

Married

1638 (44.6%)

33158 (48.2%)

Separated/Divorced

367 (10%)

7403 (10.8%)

Widowed

838 (22.8%)

13286 (19.3%)

Unknown

363 (9.9%)

2658 (3.9%)

Single primary

3386 (92.2%)

63728 (92.6%)

Multiple primary

285 (7.8%)

5092 (7.4%)

Single

3337 (90.9%)

62651 (91.0%)

<0.0001

Number of Primary
0.4115

Number of Cancer Diagnoses

Synchronous

139 (3.9%)

2350 (3.4%)

Non-synchronous

101 (2.8%)

1941 (2.8%)

Unknown

94 (2.5%)

1878 (2.7%)

0.6082
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Synchronous Cancers
Synchronous

139 (3.9%)

2350 (3.4%)

Non-synchronous/single primary

3438 (96.1%)

64592 (96.5%)

0.2358

Stage
Early stage (I and II)

1061 (28.9%)

18715 (27.2%)

Late stage (III and IV)

2014 (54.9%)

39260 (57.1%)

Unknown

596 (16.2%)

10845 (15.8%)

I

250 (6.8%)

4433 (6.4%)

II

508 (13.8%)

8310 (12.1%)

III

1006 (27.4%)

20793 (30.2%)

IV

498 (13.6%)

8461 (12.3%)

Unknown

1409 (38.4%)

26823 (39%)

0.0280

Grade
<0.0001

Histologic Type ICD-O-3
Epithelial tumors

2267 (61.8%)

44180 (64.2%)

Sex chord-stromal tumors

285 (7.8%)

4599 (6.7%)

Germ cell tumors

65 (1.8%)

1334 (1.9%)

1054 (28.7%)

18707 (27.2%)

Unspecified/Others/Borderline
tumors

0.0051

*For the variable Appalachian, descriptive statistics were only calculated for Kentucky due to the fact that only 2
out of 16 regions included in the Non-Kentucky SEER group had Appalachian regions.
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Table 2. Distribution of Multiple Primary and Synchronous Cancer by SEER and KY, 2000-2014

KY

SEER

Variable
Multiple Primary
Early Stage
Single Primary
Multiple Primary
Late Stage
Single Primary
Multiple Primary
Synchronous Cancer
Early Stage
Non-sync/Single
Sync Cancer
Late Stage
Non-sync/Single
Sync Cancer

p-value
N

%

N

%

901
160

84.9%
15.1%

16417
2298

87.7%
12.3%

0.0071

1911
103

94.9%
5.1%

36995
2265

94.2%
5.8%

0.2176

957
76

92.6%
7.4%

17269
1117

93.9%
6.1%

0.0950

1948
52

97.4%
2.6%

37810
996

97.4%
2.6%

0.9267

In the analysis for synchronous cancers, 1,972 observations were missing/deleted due to the fact that they
did not have information on their date of second cancer diagnosis and could not be classified as
synchronous or non-synchronous.
Note: For this table, Unknown category for stage was not included for multiple and synchronous cancers.
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Table 3. Descriptive statistics of ovarian cancer patients by multiple primary cancer status (N=72,491)
Kentucky
Variable

Age at diagnosis (years)
20-49
50-64
65-74
75+
Year of diagnosis
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
Race

Single

Multiple

(3337, 4.6%)

Non-Kentucky SEER
Single

Multiple

(285, 0.39%)

(63728, 88.0%)

(5092, 7.0%)

645(19.0%)
1089 (32.2%)
729 (21.5%)
923 (27.3%)

73 (25.6%)
115 (40.4%)
60 (21.1%)
37 (13.0%)

<0.0001

12765 (20.0%)
21712 (34.1%)
13201 (20.7%)
16050 (25.2%)

1243 (24.4%)
2089 (41.0%)
1027 (20.2%)
733 (14.4%)

<0.0001

274 (8.1%)
234 (6.9%)
244 (7.2%)
217 (6.4%)
244 (7.2%)
224 (6.6%)
248 (7.3%)
215 (6.4%)
216 (6.4%)
205 (6.1%)
207 (6.1%)
223 (6.6%)
228 (6.7%)
220 (6.5%)
187 (5.5%)

27 (9.5%)
14 (4.9%)
17 (6.0%)
17 (6.0%)
21 (7.4%)
24 (8.4%)
17 (6.0%)
25 (8.8%)
29 (10.2%)
29 (10.2%)
18 (6.3%)
12 (4.2%)
11 (3.9%)
15 (5.3%)
9 (3.2%)

0.0109

4145 (6.5%)
4274 (6.7%)
4248 (6.7%)
4175 (6.6%)
4093 (6.4%)
4114 (6.5%)
4164 (6.5%)
4241 (67%)
4398 (6.9%)
4290 (6.7%)
4333 (6.8%)
4271 (6.7%)
4307 (6.8%)
4267 (6.7%)
4408 (6.9%)

402 (7.9%)
413 (8.1%)
371 (7.3%)
382 (7.5%)
359 (7.1%)
337 (6.6%)
403 (7.9%)
344 (6.8%)
360 (7.1%)
348 (6.8%)
285 (5.6%)
289 (5.7%)
286 (5.6%)
291 (5.7%)
222 (4.4%)

<0.0001

P-value

P-value
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White

3224 (95.2%)

272 (95.4%)

Black

141 (4.2%)

12 (4.2%)

Other (American Indian/AK
Native, Asian/Pacific Islander)

14 (0.1%)

1 (0.4%)

Unknown

7 (0.2%)

0 (0.0%)

1036 (30.6%)

93 (32.6%)

0.8925

52553 (82.5%)

4335 (85.1%)

5505 (8.6%)

337 (6.6%)

5373 (8.4%)

413 (8.1%)

297 (0.5%)

7 (0.1%)

-

-

-

-

57445 (90.1%)

4632 (91.0%)

<0.0001

*Appalachian Status (Kentucky)
Appalachian
Non-Appalachian

0.4746

2350 (69.4%)

192 (67.4%)

Urban

1809 (53.4%)

158 (55.4%)

Rural

1577 (46.6%)

127 (44.6%)

6216 (9.8%)

454 (8.9%)

Unknown

0 (0.0)

0 (0,0)

67 (0.1%)

6 (0.1%)

Single

421 (12.4%)

44 (15.4%)

11268 (17.7%)

1047 (20.6%)

Married

1510 (44.6%)

128 (44.9%)

30500 (47.9%)

2658 (52.2%)

6859 (10.8%)

544 (10.7%)

-

**Urban/Rural

0.5129

0.1463

Marital Status at Diagnosis

0.0224

Separated/Divorced

329 (9.7%)

38 (13.3%)

Widowed

792 (23.4%)

46 (16.1%)

12621 (19.8%)

665 (13.1%)

Unknown

334 (9.9%)

29 (10.2%)

2480 (3.9%)

178 (3.5%)

Early (I and II)

901 (26.6%)

160 (56.1%)

16417 (25.8%)

2298 (45.1%)

Late (III and IV)

1911 (56.4%)

103 (36.1%)

36995 (58.1%)

2265 (44.5%)

Unknown

574 (17.0%)

22 (7.7%)

10316 (16.2%)

529 (10.4%)

I

210 (6.2%)

40 (14.0%)

3789 (6.0%)

644 (12.7%)

II

438 (12.9%)

70 (24.6%)

7314 (11.5%)

996 (19.6%)

19228 (30.2%)

1565 (30.7%)

<0.0001

Stage

<0.0001

<0.0001

Grade

<0.0001

III

913 (27.0%)

93 (32.6%)

IV

466 (13.8%)

32 (11.2%)

7908 (12.4%)

553 (10.9%)

Unknown

1359 (40.1%)

50 (17.5%)

25489 (40.0%)

1334 (26.2%)

<0.0001
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Histologic Type ICD-O-3
Epithelial tumors
Sex chord-stromal tumors
Germ cell tumors
Unspecified/Others/Borderline
tumors

2062 (60.9%)

205 (71.9%)

252 (7.4%)

33 (11.6%)

61 (1.8%)

4 (1.4%)

1011 (29.9%)

43 (15.1%)

<0.0001

40400 (63.4%)

3780 (74.2%)

4149 (6.5%)

450 (8.8%)

1279 (2.0%)

55 (1.1%)

17900 (28.1%)

807 (15.9%)

<0.0001

*For the variable Appalachian, descriptive statistics were only calculated for Kentucky due to the fact that only 2
out of 16 regions included in the Non-Kentucky SEER group had Appalachian regions.
**For the variable urban, chi-square values had to be calculated without the unknown category within Kentucky
due to the cells that had a value of zero.
Table 4. Descriptive statistics of ovarian cancer patients by synchronous cancer status (N=70519)
Kentucky
Variable

Synchronous
(139, 3.9%)

Nonsynchronous

Non-Kentucky SEER
P-value

(3438, 96.1%)

Age at diagnosis (years)
20-49
50-64
65-74
75+

45 (32.4)
48 (34.5)
23 (16.6)
23 (16.6)

667 (19.4)
1131 (32.9)
745 (21.7)
895 (26.0)

Year of diagnosis
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014

6 (4.3)
5 (3.6)
8 (5.8)
5 (3.6)
7 (5.0)
16 (11.5)
7 (5.0)
14 (10.1)
11 (7.9)
14 (10.1)
12 (8.6)
7 (5.0)
7 (5.0)
11 (7.9)
9 (6.5)

289 (8.4)
239 (7.0)
245 (7.1)
225 (6.5)
250 (7.3)
227 (6.6)
254 (7.4)
425 (6.3)
224 (6.5)
210 (6.1)
204 (5.9)
224 (6.5)
225 (6.5)
220 (6.4)
184 (5.4)

0.0005

0.0499

Synchronous

Nonsynchronous

(2350, 3.5%)

(64592, 96.5%)

694 (29.5)
922 (39.2)
406 (17.3)
328 (14.0)

13079 (20.3)
22366 (34.6)
13517 (20.9)
15630 (24.2)

132 (5.6)
140 (6.0)
128 (5.5)
143 (6.1)
138 (5.9)
148 (6.3)
156 (6.6)
152 (6.5)
158 (6.7)
161 (6.9)
161 (6.9)
153 (6.5)
170 (7.2)
210 (8.9)
200 (8.5)

4270 (6.6)
4432 (6.9)
4326 (6.7)
4300(6.7)
4185 (6.5)
4167 (6.5)
4282 (6.6)
4294 (6.7)
4459 (6.9)
4365 (6.8)
4337 (6.7)
4285 (6.6)
4310 (6.7)
4244 (6.6)
4333 (6.7)

P-value

<0.0001

<0.0001
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Race
White

135 (97.1)

3271 (95.1)

1974 (84.0)

53346 (82.6)

Black

4 (2.9)

145 (4.2)

159 (6.8)

5507 (8.5)

210 (8.9)

5461 (8.5)

7 (0.3)

278 (0.4)

-

-

Other (American Indian/AK
Native, Asian/Pacific Islander)

0 (0.0)

15 (0.4)

Unknown

0 (0.0)

7 (0.2)

47 (33.8)

1048 (30.5)

92 (66.2)

2390 (69.5)

Urban

76 (54.7)

1842 (53.6)

Rural

63 (45.3)

1596 (46.4)

Unknown

0 (0.0)

0 (0.0)

0.8594

0.0155

*Appalachian Status (Kentucky)
Appalachian
0.4036

Non-Appalachian

-

-

2158 (91.8)

58258 (90.2)

192 (8.2)

6266 (9.7)

0 (0.0)

68 (0.1)

**Urban/Rural

0.7990

0.0130

Marital Status at Diagnosis
Single

27 (19.4)

425 (12.4)

575 (24.5)

11478 (17.8)

Married

65 (46.8)

1545 (44.9)

1167 (49.7)

31309 (48.5)

Separated/Divorced

13 (9.4)

339 (9.9)

233 (9.9)

6903 (10.7)

0.0471

Widowed

27 (19.4)

776 (22.6)

284 (12.1)

12393 (19.2)

Unknown

7 (5.0)

353 (10.3)

91 (3.9)

2509 (3.9)

Early (I and II)

76 (54.7%)

957 (27.8%)

1117 (47.5%)

17269 (26.7%)

Late (III and IV)

52 (37.4%)

1948 (56.7%)

996 (42.4%)

37810 (58.5%)

Unknown

11 (7.9%)

533 (15.5%)

237 (10.1%)

9513 (14.7%)

<0.0001

Stage

<0.0001

<0.0001

Grade
I

22 (15.8)

222 (6.5)

376 (16.0)

3978 (6.2)

II

40 (28.9)

456 (13.3)

546 (23.2)

7637 (11.8)

III

43 (30.9)

948 (27.6)

585 (24.9)

19914 (30.8)

IV

15 (10.8)

478 (13.9)

220 (9.4)

8130 (12.6)

<0.0001

<0.0001
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Unknown

19 (13.7)

1334 (38.8)

623 (26.5)

24933 (38.6)

Epithelial tumors

102 (73.4)

2135 (62.1)

1687 (71.8)

41831 (64.8)

Sex chord-stromal tumors

17 (12.2)

261 (7.6)

245 (10.4)

4277 (6.6)

20 (1.5)

1301 (98.5)

Histologic Type ICD-O-3

Germ cell tumors

1 (0.7)

63 (1.83)

0.0005

Unspecified/Others/Borderline
19 (13.7)
979 (28.5)
398 (16.9)
17183 (26.6)
tumors
*For the variable Appalachian, descriptive statistics were only calculated for Kentucky due to the fact that only 2
out of 16 regions included in the Non-Kentucky SEER group had Appalachian regions.
**For the variable urban, chi-square values had to be calculated without the unknown category due to the cells that
had a value of zero.

Table 5. Distribution of subsequent cancer sites for multiple primary and synchronous cancer in ovarian cancer
patients
Kentucky
Non-Kentucky
SEER

Multiple Primary Cancers
Cancer Site

Uterine
Breast
Lung and Bronchus
Ovary
Other female genital
Kidney and Renal Pelvis
All Others
Synchronous Cancers
Cancer Site

Uterine
Ovary
Breast
Lung and Bronchus
Other female genital

P-value
N=285
89
39
14
13
6
5
119

%
31.2
13.7
4.9
4.6
2.1
1.8
41.8

N=2350
1322
177
57
69
66
58
552

%
56.3
7.5
2.4
1.4
2.8
2.5
23.5

0.4992

P-value
N=139

%

N=2350

%

85
10
9
7
6

61.2
7.2
6.5
5.0
4.3

1322
118
177
57
66

56.3
5.0
7.5
2.4
2.8

0.0443

<0.0001

43
Kidney and Renal Pelvis
All Others

4
18

2.9
12.9

58
552

2.5
23.5

Figure 1. Kaplan Meier survival curves for multiple primary cases comparing SEER and Kentucky

Log Rank-test: 0.7093
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Figure 2. Kaplan Meier survival curves for early stage cancer in multiple primary cases comparing SEER
and Kentucky

45
Log Rank test: 0.5805

Figure 3. Kaplan Meier survival curves for late stage cancer in multiple primary cases comparing SEER
and Kentucky

46
Log Rank test: 0.0329

Figure 4. Kaplan Meier survival curves for synchronous cases comparing SEER and Kentucky

47
Log Rank test: 0.8419

Figure 5. Kaplan Meier survival curves for early stage cancer in synchronous cases comparing SEER and
Kentucky
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Log Rank test: 0.9833

Figure 6. Kaplan Meier survival curves for late stage cancer in synchronous cases comparing SEER and
Kentucky
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Log Rank test: 0.0353

Table 6. Logistic model for multiple primary cases adjusted for stage of disease
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Early and Late Stage
Variable

Early Stage Only

Adjusted
OR

95% CI

P

Adjusted
OR

95% CI

P

Ref.
1.06

(0.93, 1.22)

0.4008

Ref.
1.23

(1.02, 1.47)

0.0308

Ref.
1.09
1.06
0.79

(1.01, 1.90)
(0.96, 1.16)
(0.70, 0.88)

<0.0001
0.0080
<0.0001

Ref.
1.06
1.16
0.86

(0.96, 1.18)
(1.08, 1.33)
(0.72, 1.03)

0.2144
0.0046
0.0068

0.96

(0.96, 0.97)

<0.0001

0.94

(0.94, 0.96)

<.0001

Ref.
0.76
0.83

(0.67, 0.87)
(0.74, 0.93)

0.1260
0.0244

Ref.
0.68
0.76

(0.56, 0.83)
(0.65, 0.89)

0.6017
0.1543

0.27

(0.12, 0.60)

0.0051

0.31

(0.13, 0.77)

0.0396

Ref.
0.94

(0.85, 1.04)

0.2253

Ref.
0.94

(0.81, 1.08)

0.3915

Single
Married
Separated/Divorced
Widowed
Unknown

Ref.
0.89
0.89
0.83
0.85

(0.82, 0.96)
(0.80, 1.00)
(0.73, 0.93)
(0.72, 1.02)

0.9026
0.9548
0.0872
0.5331

Ref.
0.85
0.87
0.82
0.88

(0.76 0.95)
(0.74, 1.02)
(0.68, 0.98)
(0.70, 1.11)

0.3725
0.8136
0.2704
0.9751

Grade I
Grade II
Grade III
Grade IV
Unknown

Ref.
0.93
0.69
0.63
0.54

(0.82, 1.02)
(0.63, 0.77)
(0.56, 0.72)
(0.49, 0.61)

<0.0001
0.0205
<0.0001
<0.0001

Ref.
0.94
0.70
0.58
0.60

(0.83, 1.06)
(0.61, 0.79)
(0.48, 0.70)
(0.53, 0.69)

<.0001
0.1175
0.0002
<.0001

Ref.
1.19
0.32
0.76

(1.07, 1.32)
(0.24, 0.44)
(0.69, 0.84)

<0.0001
<0.0001
0.5550

Ref.
1.06
0.28
0.72

(0.93, 1.22)
(0.20 0.40)
(0.61, 0.85)

<.0001
<.0001
0.4621

Location
Non-Kentucky SEER Areas
Kentucky
Age at diagnosis (years)
20-49
50-64
65-74
75+
Year of diagnosis
2000-2014
Race
White
Black
Other (American Indian/AK Native,
Asian/Pacific Islander)
Unknown
Urban/Rural
Urban
Rural
Marital Status at Diagnosis

Grade

Histologic Type ICD-O-3
Epithelial tumors
Sex chord-stromal tumors
Germ cell tumors
Unspecified/Others/Borderline tumors
CI, confidence interval; OR, odds ratio.
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Table 7. Logistic model for synchronous cases adjusted for stage of disease
Early and Late Stage
Variable

Early Stage Only

Adjusted
OR

95% CI

P

Adjusted
OR

95% CI

P

Ref.
1.14

(0.94, 1.38)

0.1949

Ref.
1.24

(0.96, 1.60)

0.1008

Ref.
0.88
0.73
0.64

(0.78, 0.97)
(0.64, 0.84)
(0.55, 0.76)

0.0170
0.0505
<0.0001

Ref.
0.83
0.67
0.60

(0.72, 0.95)
(0.54, 0.81)
(0.47, 0.78)

0.1128
0.0705
0.0140

1.03

(1.02, 1.04)

<0.0001

1.03

(1.01, 1.04)

0.0003

Ref.
0.74
0.90

(0.61, 0.88)
(0.77, 1.05)

0.8249
0.1480

Ref.
0.58
0.77

(0.43 0.77)
(0.63, 0.95)

0.2102
0.5376

0.49

(0.22, 1.12)

0.1737

0.56

(0.23, 1.39)

0.5033

Ref.
0.94

(0.81, 1.09)

0.3989

Ref.
0.91

(0.74, 1.12)

0.3737

Single
Married
Separated/Divorced
Widowed
Unknown

Ref.
0.75
0.72
0.74
0.75

(0.68, 0.84)
(0.61, 0.85)
(0.63, 0.88)
(0.59, 0.96)

0.2580
0.1698
0.3403
0.6361

Ref.
0.77
0.74
0.69
0.70

(0.67, 0.89)
(0.59, 0.94)
(0.53, 0.91)
(0.50, 0.97)

0.9542
0.6651
0.2993
0.4283

Grade I
Grade II
Grade III
Grade IV
Unknown

Ref.
0.92
0.45
0.39
0.43

(0.80, 1.05)
(0.39, 0.52)
(0.33, 0.47)
(0.37, 0.49)

<0.0001
<0.0001
<0.0001
<0.0001

Ref.
0.95
0.51
0.38
0.47

(0.81, 1.11)
(0.43, 0.62)
(0.29, 0.49)
(0.39, 0.56)

<0.0001
0.0067
<0.0001
<0.0001

Ref.
1.41
0.20
0.83

(1.23, 1.62)
(0.12, 0.33)
(0.72, 0.96)

<0.0001
<0.0001
0.0333

Ref.
1.18
0.16
0.66

(0.98, 1.41)
(0.09, 0.29)
(0.51, 0.85)

<0.0001
<0.0001
0.3861

Location
Non-Kentucky SEER Areas
Kentucky
Age at diagnosis (years)
20-49
50-64
65-74
75+
Year of diagnosis
2000-2014
Race
White
Black
Other (American Indian/AK Native,
Asian/Pacific Islander)
Unknown
Urban/Rural
Urban
Rural
Marital Status at Diagnosis

Grade

Histologic Type ICD-O-3
Epithelial tumors
Sex chord-stromal tumors
Germ cell tumors
Unspecified/Others/Borderline tumors
CI, confidence interval; OR, odds ratio.
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Table 8. Cox proportional hazard model for multiple primary cases adjusted for stage
Early and Late Stage
Variable

Early Stage Only

Adjusted
HR

95% CI

P

Adjusted
HR

95% CI

P

Ref.
1.06

(0.92, 1.22)

0.4330

Ref.
1.04

(0.91, 1.19)

0.6061

Ref.
1.10
1.15
1.07

(1.02, 1.20)
(1.05, 1.27)
(0.95, 1.20)

0.0177
0.0046
0.2997

Ref.
1.14
1.19
1.05

(1.05, 1.23)
(1.08, 1.30)
(0.94, 1.18)

0.0012
0.0004
0.3763

1.02

(1.01, 1.03)

<0.0001

1.03

(1.02, 1.04)

<0.0001

Ref.
0.84
0.84
0.34

(0.74, 0.95)
(0.75, 0.95)
(0.15, 0.75)

0.0079
0.0048
0.0076

Ref.
0.88
0.86
0.33

(0.78, 0.99)
(0.77, 0.96)
(0.16, 0.69)

0.0372
0.0070
0.0033

Ref.
0.97

(0.88, 1.08)

0.5845

Ref.
0.96

(0.87, 1.06)

0.4488

Single
Married
Separated/Divorced
Widowed
Unknown

Ref.
0.83
0.84
0.84
0.88

(0.76, 0.90)
(0.74, 0.94)
(0.74, 0.95)
(0.73, 1.04)

<0.0001
0.0036
0.0060
0.1381

Ref.
0.84
0.86
0.85
0.88

(0.77, 0.91)
(0.77, 0.97)
(0.76, 0.96)
(0.75, 1.03)

<.0001
0.0098
0.0068
0.1105

Grade I
Grade II
Grade III
Grade IV
Unknown

Ref.
0.96
0.69
0.61
0.62

(0.86, 1.07)
(0.62, 0.77)
(0.53, 0.69)
(0.55, 0.69)

0.4540
<0.0001
<0.0001
<0.0001

Ref.
0.96
0.69
0.60
0.61

(0.86, 1.06)
(0.63, 0.77)
(0.53, 0.69)
(0.55, 0.68)

0.4114
<0.0001
<0.0001
<0.0001

Ref.
1.17
0.28
1.02

(1.05, 1.30)
(0.20, 0.40)
(0.92, 1.12)

0.0055
<0.0001
0.7385

Ref.
1.13
0.36
1.03

(1.02, 1.26)
(0.27, 0.48)
(0.94, 1.13)

0.0195
<0.0001
0.5008

Location
Non-Kentucky SEER Areas
Kentucky
Age at diagnosis (years)
20-49
50-64
65-74
75+
Year of diagnosis
2000-2014
Race
White
Black
Other (American Indian/AK Native,
Asian/Pacific Islander)
Unknown
Urban/Rural
Urban
Rural
Marital Status at Diagnosis

Grade

Histologic Type ICD-O-3
Epithelial tumors
Sex chord-stromal tumors
Germ cell tumors
Unspecified/Others/Borderline tumors
CI, confidence interval; HR, hazard ratio.
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Note: In the Cox regression analysis, there were only 55940 observations for the early/late stage group and only 18859
observations used for early stage.

54
Acknowledgements:

We offer thanks to the Kentucky Cancer Registry for providing ovarian cancer data that was
used in this study. I would also like to acknowledge the individuals who assisted in the
completion of this study. I would like to express my appreciation to Drs. Bin Huang, Steve
Fleming, and Thomas Tucker for their guidance and support on this project.

